10x Genomics, Inc.
TXGAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Nov 6, 2026 | UBS | Douglas Schenkel | $61.00(+5%) | $58.06 | StreetInsider |
| Nov 6, 2026 | Stifel Nicolaus | Daniel Arias | $68.00(+17%) | $58.06 | StreetInsider |
| Oct 13, 2026 | Stifel Nicolaus | $70.00(-4%) | $72.68 | StreetInsider | |
| Oct 12, 2026 | Morgan Stanley | $70.00(-11%) | $78.95 | TheFly | |
| Oct 12, 2026 | Canaccord Genuity | Kyle Mikson | $100.00(+24%) | $80.65 | TheFly |
| Oct 7, 2026 | Barclays | $110.00(+36%) | $80.66 | TheFly | |
| Sep 29, 2026 | Leerink Partners | $90.00(+2%) | $88.42 | TheFly | |
| Sep 28, 2026 | Argus Research | $110.00(+28%) | $85.71 | TheFly | |
| Sep 28, 2026 | Piper Sandler | $80.00(-7%) | $85.71 | TheFly | |
| Sep 9, 2026 | UBS | Doug Schenkel | $68.00(+4%) | $65.60 | TheFly |
| Sep 1, 2026 | RBC Capital | Dan Leonard | $70.00(+12%) | $62.45 | StreetInsider |
| Aug 12, 2026 | Stephens | Mason Carrico | $65.00(+11%) | $58.34 | TheFly |
| Aug 10, 2026 | Piper Sandler | $47.00(-10%) | $52.03 | TheFly | |
| Aug 10, 2026 | Canaccord Genuity | Kyle Mikson | $60.00(+15%) | $52.03 | StreetInsider |
| Aug 7, 2026 | Morgan Stanley | $40.00(-17%) | $48.31 | TheFly | |
| Aug 7, 2026 | Stifel Nicolaus | $50.00(+6%) | $47.15 | TheFly | |
| Jul 17, 2026 | Leerink Partners | $40.00(-9%) | $44.12 | TheFly | |
| Jul 14, 2026 | Canaccord Genuity | Kyle Mikson | $50.00(+20%) | $41.77 | TheFly |
| Jul 9, 2026 | Morgan Stanley | Kallum Titchmarsh | $37.00(-1%) | $37.47 | TheFly |
| Jun 24, 2026 | Barclays | Luke Sergott | $40.00(+26%) | $31.87 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| UBS | maintain | Neutral | Nov 6, 2026 |
| Stifel | maintain | Buy | Nov 6, 2026 |
| Citigroup | maintain | Neutral | Nov 6, 2026 |
| Morgan Stanley | maintain | Equal Weight | Oct 13, 2026 |
| TD Cowen | maintain | Hold | Oct 13, 2026 |
| Canaccord Genuity | maintain | Buy | Oct 12, 2026 |
| Barclays | maintain | Overweight | Oct 7, 2026 |
| Leerink Partners | maintain | Market Perform | Sep 29, 2026 |
| Piper Sandler | maintain | Neutral | Sep 28, 2026 |
| UBS | maintain | Neutral | Sep 9, 2026 |
| Stephens & Co. | maintain | Overweight | Aug 12, 2026 |
| Canaccord Genuity | maintain | Buy | Aug 10, 2026 |
| Piper Sandler | maintain | Neutral | Aug 10, 2026 |
| Citigroup | maintain | Neutral | Aug 7, 2026 |
| Morgan Stanley | maintain | Equal Weight | Aug 7, 2026 |
| Leerink Partners | maintain | Market Perform | Jul 17, 2026 |
| Canaccord Genuity | maintain | Buy | Jul 14, 2026 |
| Morgan Stanley | maintain | Equal Weight | Jul 9, 2026 |
| Citigroup | maintain | Neutral | Jul 8, 2026 |
| Piper Sandler | maintain | Neutral | Jul 1, 2026 |
| Barclays | maintain | Overweight | Jun 24, 2026 |
| Morgan Stanley | maintain | Equal Weight | May 12, 2026 |
| JP Morgan | maintain | Neutral | May 12, 2026 |
| B of A Securities | maintain | Neutral | Apr 20, 2026 |
| Canaccord Genuity | maintain | Buy | Apr 20, 2026 |
Earnings History
Next report: Feb 11, 2027 · EPS est. $-0.18| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 5, 2026 | $-0.15 | $-0.27 | $150.7M | $148.0M |
| Aug 6, 2026 | $-0.14 | $-0.24 | $151.0M | $146.7M |
| May 7, 2026 | $-0.10 | $-0.29 | $150.8M | $146.4M |
| Feb 12, 2026 | $-0.13 | $-0.19 | $166.0M | $159.7M |
| Nov 6, 2025 | $-0.22 | $-0.07 | $149.0M | $142.5M |
| Aug 7, 2025 | $0.28 | $-0.35 | $172.9M | $139.5M |
| May 8, 2025 | $-0.36 | $-0.45 | $154.9M | $145.3M |
| Feb 12, 2025 | $-0.40 | $-0.29 | $165.0M | $165.0M |
News
Torex Gold Resources TSE: TXG reported a 37% quarter-over-quarter increase in production in the third quarter of 2026, as higher grades and improved gold recovery boosted margins and cash flow at its Morelos complex.
Chicago Partners Investment Group LLC lowered its position in shares of 10x Genomics (NASDAQ: TXG) by 29.3% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 27,956 shares of the company's stock after selling 11,605 shares during the
TXG launches Sentira Single Cell, a Claude-powered AI tool to simplify complex data analysis, accelerate research and unlock recurring revenue potential.
10x Genomics raises its 2026 revenue outlook on strong Atera demand and spatial consumables growth, but production constraints and margin pressure remain challenges.
10x Genomics NASDAQ: TXG raised its full-year revenue outlook after reporting modest third-quarter growth and increased its shipment target for its new Atera spatial biology platform.
Small-cap stocks have benefited from a range of tailwinds this year.
The headline numbers for 10x Genomics (TXG) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
10x Genomics, Inc. (TXG) Q3 2026 Earnings Call Transcript
10x Genomics (TXG) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.22 per share a year ago.
PLEASANTON, Calif., Nov. 5, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today reported financial results for the third quarter ended September 30, 2026.
Shares of Torex Gold Resources Inc. (TSE: TXG - Get Free Report) passed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of C$64.76 and traded as high as C$66.27. Torex Gold Resources shares last traded at C$65.29, with a volume of 314,994 shares. Analysts Set New Price Targets
Powered by Anthropic's Claude, Sentira Single Cell enables researchers to analyze Chromium data using natural language, accelerating the path from scientific questions to experimental conclusions PLEASANTON, Calif., Nov. 2, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced the commercial launch of Sentira Single Cell, a cloud-based agentic analysis application that puts sophisticat…
Genomics and synthetic biology are transforming healthcare through precision medicine and gene editing, putting ILMN, QURE and TXG in focus as the markets expand.
PLEASANTON, Calif., Oct. 27, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, announced today that members of its management team will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in London on Tuesday, November 17, at 4:30 p.m.
On October 16, 2026, 10x Genomics Inc (TXG) shares fell 3.5%, bringing the current price to $69.86. The stock has experienced significant price fluctuations, wi
PLEASANTON, Calif., Oct. 13, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, announced it will report financial results for the third quarter ended September 30, 2026 after market close on Thursday, November 5, 2026.
Forget the "Magnificent Seven" in favor of the "Tremendous Three"?
TXG teams up with Fred Hutchinson Cancer Center to advance precision oncology through single-cell and spatial technologies targeting two cancer types.
Multi-project collaboration with Fred Hutch Cancer Center spans biomarker discovery in bladder cancer and a single cell approach to residual disease detection in acute myeloid leukemia PLEASANTON, Calif., Oct. 7, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced a multi-project research collaboration with Fred Hutchinson Cancer Center (Fred Hutch), one of the nation's leading cance…
Torex Gold Resources (TSE: TXG) outlined plans to build on production from its Morelos property in Mexico, advance the Los Reyes development project and return capital to shareholders as it seeks to close what it described as a valuation gap. During a company presentation, Andrew, a Torex speaker, said the company's strategy rests on "strong execution,